Get started
Author

Ashley S. Pereira

ORCID: 0000-0003-4871-0856
Observed ORCID: 0000-0003-4871-0856
OpenAlex ID: A5124718436
Supplementary Data 2 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
2026 · Melissa R. Junttila, Claire E. Repellin, et al.
Supplementary Table S1 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
2026 · Melissa R. Junttila, Claire E. Repellin, et al.
Data from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
2026 · Melissa R. Junttila, Claire E. Repellin, et al.
Supplementary Fig S4 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
2026 · Melissa R. Junttila, Claire E. Repellin, et al.
Supplementary Table S4 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
2026 · Melissa R. Junttila, Claire E. Repellin, et al.
Supplementary Fig S1 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
2026 · Melissa R. Junttila, Claire E. Repellin, et al.
Supplementary Table S2 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
2026 · Melissa R. Junttila, Claire E. Repellin, et al.
SupplementaryFig S2 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
2026 · Melissa R. Junttila, Claire E. Repellin, et al.
Supplementary Fig S5 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
2026 · Melissa R. Junttila, Claire E. Repellin, et al.
Supplementary Data 1 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
2026 · Melissa R. Junttila, Claire E. Repellin, et al.
Supplementary Figure S3 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
2026 · Melissa R. Junttila, Claire E. Repellin, et al.
Supplementary Table S3 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
2026 · Melissa R. Junttila, Claire E. Repellin, et al.
Works count: 12
Citation count:
H-index:
I10-index:
Year
Topic
Type